Tapentadol is partially metabolized via the hepatic enzymes CYP2C9, CYP2C19, and CYP2D6 so it innately has interactions with medication that enrich or repress the action/expression of one or more of such enzymes, and also with substrates of those enzymes (resulting from Competitiveness to the enzyme); some enzyme mediators/substrates demand dosing https://johnnya222ypf2.blogchaat.com/profile